Presentation

BioInvent is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with five ongoing programs in phase l/ll clinical trials for the treatment of haematological and solid tumours. Further, one preclinical program in solid tumours is expected to enter clinical trial in 2023. The company’s proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.

Recent highlights
The latest NHL data in November 2021 showed increased and sustained responses to BI-1206 in relapsed patients. In May this year the FDA also cleared a potential pivotal Phase 2 trial (expected start in 1H 2023). BioInvent also announced a deal with Exelixis to co-develop new preclinical antibodies, where BioInvent received USD 25m as upfront payment.

Outlook
With five ongoing programs in the clinics, we expect catalysts will continue to emerge. We can expect more data readouts over the next six months, which include BI-1206+Rituximab (NHL) follow-up and dose expansion data, preliminary safety and efficacy data from BI-1206+Keytruda, BT-001 and BI-1808 (solid tumours).